Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Asparaginase-Associated Toxicities and Hypersensitivity Reactions in Pediatric and Adolescent Down Syndrome Patients with Acute Lymphoblastic Leukemia or Lymphoma

Van Thu Huynh, Carol Hwang Lin, Sonia Morales, Anurag K. Agrawal, Christine L Phillips, Keith J. August, Erin M. Guest, Beth Apsel Winger, Catherine Aftandilian, Janel R. Long-Boyle, Kirsten Kasper, Keri Zabokrtsky

Blood (2023) 142 (Supplement 1): 5809.

https://doi.org/10.1182/blood-2023-190734

Published: 2023

Journal Articles

Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia; A Merged Analysis from the Prwcc and PHIS

Blood (2023) 142 (Supplement 1): 6912.

https://doi.org/10.1182/blood-2023-187462

Published: 2023

Journal Articles

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Matthew J. Frigault, Richard T Maziarz, Jae H. Park, Aleksandr Lazaryan, Nirav N. Shah, Jakub Svoboda, Lazaros J. Lekakis, Ran Reshef, Christine L Phillips, Lea M Burke, Jing Lei, Rodica Morariu-Zamfir, John F. DiPersio

Blood (2023) 142 (Supplement 1): 356.

https://doi.org/10.1182/blood-2023-180205

Published: 2023

Journal Articles

Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 2133.

https://doi.org/10.1182/blood-2023-189921

Published: 2023

Journal Articles

Pharmacogenomics to Predict Asparaginase Premedication-Related Hypersensitivity in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma

Vivek M. Shastri, Jennifer Ahmed, Eva Spin, Yeniffer Nunez, Sonia Morales, Anurag Agrawal, Christine L Phillips, Keith J. August, Erin M. Guest, Beth Apsel Winger, Catherine Aftandilian, Van Thu Huynh, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 6067.

https://doi.org/10.1182/blood-2023-187111

Published: 2023

Journal Articles

Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults

Blood (2022) 140 (Supplement 1): 4661–4663.

https://doi.org/10.1182/blood-2022-169603

Published: 2022

Journal Articles

Premedication and Therapeutic Drug Monitoring (TDM) for Pegaspargase: A Prospective Multicenter Multi-Ethnic Study of Pediatric and Adolescent Patients

Van T Huynh, Sonia Morales, Anurag K. Agrawal, Christine L. Phillips, Keith J August, Erin Guest, Beth Apsel Winger, Catherine Aftandilian, Janel R. Long-Boyle, Kirsten Kasper, Keri Zabokrtsky, Carol Hwang Lin

Blood (2022) 140 (Supplement 1): 8893–8895.

https://doi.org/10.1182/blood-2022-159255

Published: 2022

Journal Articles

Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Blood (2021) 138 (21): 2138–2142.

https://doi.org/10.1182/blood.2021012392

Published: 2021

Journal Articles

Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Samuel John, Michael A. Pulsipher, Amy Moskop, Zhen-Huan Hu, Christine L. Phillips, Erin Marie Hall, Steven P. Margossian, Sarah Nikiforow, Paul L. Martin, Benjamin Oshrine, Amy K. Keating, Rayne H. Rouce, Ranjan Tiwari, Santiago Redondo, Jennifer Willert, Abhijit Agarwal, Marcelo C Pasquini, Stephan A. Grupp

Blood (2021) 138 (Supplement 1): 428.

https://doi.org/10.1182/blood-2021-146393

Published: 2021

Journal Articles

Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-136674

Published: 2020

Journal Articles

HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia

Michael W Boyer, MD, Sonali Chaudhury, MBBS,MD, Kara L Davis, DO, Timothy Alan Driscoll, MD, Stephan A Grupp, MD PhD, Michelle Hermiston, MD PhD, Samuel John, MD, Amy K Keating, MD PhD, Christina Kovacs, BS, JD, Andrea Magley, BS, Gary Douglas Myers, MD, Christine L Phillips, MD, Michael A Pulsipher, MD, Das Purkayastha, PhD, Julie-An Talano, MD, Jennifer Willert, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136340

Published: 2020

Journal Articles

Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-134472

Published: 2020

Journal Articles

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Laura Agresta, MD, Maureen M O'Brien, MD, Kana Mizuno, PhD, Robin Norris, MD MS, MPH, Erin H. Breese, MD PhD, Christine L Phillips, MD, Karen Burns, MD, Benjamin Mizukawa, Lynn Lee, MD, Adam Lane, PhD, Robert B. Lorsbach, MD PhD, Thomas D. Ryan, MD PhD, Pankaj B. Desai, PhD, Alexander A. Vinks, PharmD, PhD, H. Leighton Grimes, PhD, John P Perentesis, Michael J. Absalon, MD PhD

Blood (2019) 134 (Supplement_1): 3830.

https://doi.org/10.1182/blood-2019-121514

Published: 2019

Journal Articles

A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia

Michael J. Absalon, MD PhD, Erin H. Breese, MD PhD, Lynn Lee, MD, Maureen M O'Brien, MD MS, Christine L Phillips, MD, Karen Burns, MD, Benjamin Mizukawa, MD, Qi An, Jennifer Mangino, MD, Joel Kaplan, DO, Robin Norris, MD, John Peter Perentesis, MD

Blood (2018) 132 (Supplement 1): 336.

https://doi.org/10.1182/blood-2018-99-119618

Published: 2018

Journal Articles

CTL019 Therapy Appears Safe and Effective in Pediatric Patients with Down Syndrome with Relapsed/ Refractory (r/r) Acute Lymphoblastic Leukemia

Theodore W Laetsch, MD, Shannon L Maude, MD PhD, Stephan A Grupp, MD PhD, Michael W Boyer, MD, Andrew C Harris, MD, Muna Qayed, MDMSc, Christine L Phillips, MD, Michael A Pulsipher, MD, Henrique Bittencourt, MD PhD, Patricia A Wood, MD PhD, Karen Thudium Mueller, PharmD,MSc, Yanqui Weng, PhD, Carl H June, MD, Bruce L Levine, PhD, Hidefumi Hiramatsu, MD PhD

Blood (2017) 130 (Supplement 1): 1280.

https://doi.org/10.1182/blood.V130.Suppl_1.1280.1280

Published: 2017

Journal Articles

Exceptional Responses to Epigenetic Based Therapy in Pediatric and Young Adult Monosomy 7 MDS/AML Patients with and without TP53 Mutations

LaQuita M Jones, DO, Maureen M O'Brien, MD, Erin H. Breese, MD PhD, Karen Burns, MD, Jennifer Mangino, MD, Michael J. Absalon, MD PhD, Javier A. El-Bietar, MD, Michael Grimley, MD, Benjamin Mizukawa, MD, Lynn Lee, MD, John Peter Perentesis, MD, Christine L Phillips, MD

Blood (2017) 130 (Supplement 1): 3895.

https://doi.org/10.1182/blood.V130.Suppl_1.3895.3895

Published: 2017

Journal Articles

Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis

Shannon L Maude, MD PhD, Michael A Pulsipher, MD, Michael W Boyer, MD, Stephan A Grupp, MD PhD, Stella M Davies, MBBS, PhD, Christine L Phillips, MD, Michael R Verneris, MD, Keith J August, MD MS, Krysta Schlis, MD, Timothy A Driscoll, MD, Rajen Mody, MD MS, Christian M Capitini, MD, Carl H June, MD, Bruce L Levine, PhD, Patricia A Wood, MD PhD, Lan Yi, PhD, John E Levine, MD MS

Blood (2016) 128 (22): 2801.

https://doi.org/10.1182/blood.V128.22.2801.2801

Published: 2016

Journal Articles

Genomic Characterization Of Histiocytic Lesions Following Pediatric T-Cell Acute Lymphoblastic Leukemia

Richard McMasters, MD, Brian K. Turpin, DO, Michael J. Absalon, MD, PhD, Christine L. Phillips, MD, Karen Burns, MD, Christopher E. Dandoy, MD, Nihal Bakeer, MBBS, Jun Mo, MD, John Perentesis, MD, Maureen M. O'Brien, MD

Blood (2013) 122 (21): 4940.

https://doi.org/10.1182/blood.V122.21.4940.4940

Published: 2013

Journal Articles

Pediatric Experience with Low Dose Decitabine In Very High Risk Relapsed AML.

Christine L Phillips, MD, Stella M. Davies, MBBS, PhD, Richard McMasters, MD, Maureen O'Brien, MD, MS, Michael J. Absalon, MD, PhD, Jeffrey A. Moscow, MD, Teresa Smolarek, PhD, John P. Perentesis, MD

Blood (2010) 116 (21): 1070.

https://doi.org/10.1182/blood.V116.21.1070.1070

Published: 2010

Journal Articles

Pathway Based Evaluation of Cytarabine Pharmacogenetics in Children with Acute Myeloid Leukemia.

Kasiani C. Myers, MD, Robert B. Gerbing, MS, Todd A. Alonzo, PhD, Christine L Phillips, MD, Alan S. Gamis, MD, Gretchen A. Radloff, John Perentesis, Stella M. Davies, MBBS, PhD

Blood (2009) 114 (22): 2610.

https://doi.org/10.1182/blood.V114.22.2610.2610

Published: 2009

NARROW

Asparaginase-Associated Toxicities and Hypersensitivity Reactions in Pediatric and Adolescent Down Syndrome Patients with Acute Lymphoblastic Leukemia or Lymphoma

Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia; A Merged Analysis from the Prwcc and PHIS

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia

Pharmacogenomics to Predict Asparaginase Premedication-Related Hypersensitivity in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma

Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults

Premedication and Therapeutic Drug Monitoring (TDM) for Pegaspargase: A Prospective Multicenter Multi-Ethnic Study of Pediatric and Adolescent Patients

Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release

HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia

Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia

CTL019 Therapy Appears Safe and Effective in Pediatric Patients with Down Syndrome with Relapsed/ Refractory (r/r) Acute Lymphoblastic Leukemia

Exceptional Responses to Epigenetic Based Therapy in Pediatric and Young Adult Monosomy 7 MDS/AML Patients with and without TP53 Mutations

Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis

Genomic Characterization Of Histiocytic Lesions Following Pediatric T-Cell Acute Lymphoblastic Leukemia

Pediatric Experience with Low Dose Decitabine In Very High Risk Relapsed AML.

Pathway Based Evaluation of Cytarabine Pharmacogenetics in Children with Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only